# US 2013/0253471 A1 · Methods and Apparatus for Treating Contrast Nephropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253471 A1
- Document ID: US20130253471A1
- Status: Published application
- Kind: A1
- Application number: 13/898,830
- Filed: 2013-05-21
- Published: 2013-09-26
- Earliest claimed: 2002-04-08
- Assignees: Medtronic Ardian Luxembourg S.a.r.I.
- Inventors: Denise Demarais; Hanson Gifford, III; Mark Deem; Douglas Sutton; Howard R. Levin; Mark Gelfand
- Web page: https://patentgrep.com/patent/US20130253471A1

## CPC

- A61B 18/12: by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B 18/04: by heating (by applying electromagnetic radiation A61B18/18)
- A61B 18/1492: {having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence)}
- A61N 1/0551: {Spinal or peripheral nerve electrodes}
- A61N 1/36117: {for treating hypertension}
- A61N 7/00: Ultrasound therapy (lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 {; using ultrasound for introducing media into the body A61M37/0092})
- A61B 2018/0022: {Balloons}
- A61B 2018/00267: {having a basket shaped structure}
- A61B 2018/00404: {Blood vessels other than those in or around the heart}
- A61B 2018/00434: {Neural system}
- A61B 2018/00511: {Kidney}
- A61B 2018/00577: {Ablation}
- A61B 2018/00613: {Irreversible electroporation}
- A61B 2018/00642: {with feedback, i.e. closed loop control}
- A61B 2018/00648: {using more than one sensed parameter}
- A61B 2018/00791: {Temperature}
- A61B 2018/00875: {Resistance or impedance}
- A61N 2007/003: {Destruction of nerve tissue}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation of electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for catheter-based renal neuromodulation, the method comprising:
positioning a first catheter having a first therapeutic element in a low profile delivery configuration within a first renal blood vessel of a human patient and proximate to neural fibers innervating a first kidney of the patient,
wherein the first therapeutic element comprises a first expandable balloon sized and shaped for the first renal blood vessel, and wherein the first expandable balloon comprises a plurality of first electrodes arranged thereon,
transforming the first therapeutic element from the delivery configuration to a treatment configuration such that the first electrodes on the first expandable balloon are in contact with an inner wall of the first renal blood vessel;
thermally inhibiting neural communication along the neural fibers innervating the first kidney via thermal radio frequency (RF) energy from the first electrodes;
positioning a second catheter having a second therapeutic element in a low profile delivery configuration within a second renal blood vessel of the patient and proximate to neural fibers innervating a second kidney of the patient,
wherein the second therapeutic element comprises a second expandable balloon sized and shaped for the second renal blood vessel, and wherein the second balloon comprises a plurality of second electrodes arranged thereon;
transforming the second therapeutic element from the delivery configuration to a treatment configuration such that the plurality of second electrodes on the second expandable balloon are in contact with an inner wall of the second renal blood vessel; and
thermally inhibiting neural communication along the neural fibers innervating the second kidney via thermal RF energy from the second electrodes.

### Claim 22 (depends on 21)

The method of claim 21 wherein the first renal blood vessel has a different diameter than the second renal blood vessel, and wherein the first balloon comprises a different size than the second balloon.

### Claim 23 (depends on 21)

The method of claim 21 wherein the first renal blood vessel has the same or approximately the same diameter as the second renal blood vessel, and wherein the first balloon is the same size as the second balloon.

### Claim 24 (depends on 21)

The method of claim 21, further comprising removing the first catheter from the first renal blood vessel of the patient before positioning the second catheter within the second renal blood vessel of the patient.

### Claim 25 (depends on 21)

The method of claim 21 wherein positioning the first catheter within the first renal blood vessel of the patient and positioning the second catheter within the second renal blood vessel of the patient occur simultaneously.

### Claim 26 (depends on 21)

The method of claim 21 wherein:
positioning the first catheter within the first renal blood vessel of the patient comprises intravascularly delivering the first catheter to the first renal blood vessel over a first guidewire; and
positioning the second catheter within the second renal blood vessel of the patient comprises intravascularly delivering the second catheter to the second renal blood vessel over a second guidewire.

### Claim 27 (depends on 21)

The method of claim 21 wherein:
thermally inhibiting neural communication along the neural fibers innervating the first kidney comprises ablating the neural fibers innervating the first kidney; and
thermally inhibiting neural communication along the neural fibers innervating the second kidney comprises ablating the neural fibers innervating the second kidney.

### Claim 28 (depends on 21)

The method of claim 21 wherein:
thermally inhibiting neural communication along the neural fibers innervating the first kidney comprises denervating the first kidney of the patient; and
thermally inhibiting neural communication along the neural fibers innervating the second kidney comprises denervating the second kidney of the patient.

### Claim 29 (depends on 21)

The method of claim 21 wherein:
thermally inhibiting neural communication along the neural fibers innervating the first kidney comprises denervating the first kidney of the patient; and
thermally inhibiting neural communication along the neural fibers innervating the second kidney comprises denervating the second kidney of the patient.

### Claim 30 (depends on 21)

The method of claim 21 wherein:
thermally inhibiting neural communication along the neural fibers innervating the first kidney comprises reducing renal sympathetic nerve activity of the first kidney; and
thermally inhibiting neural communication along the neural fibers innervating the second kidney comprises reducing renal sympathetic nerve activity of the second kidney.

### Claim 31 (depends on 21)

The method of claim 21 wherein:
transforming the first therapeutic element from the delivery configuration to the treatment configuration further comprises occluding blood flow in the first renal blood vessel via the first expandable balloon; and
transforming the second therapeutic element from the delivery configuration to the treatment configuration further comprises occluding blood flow in the second renal blood vessel via the second expandable balloon.

### Claim 32 (depends on 21)

The method of claim 21 wherein the first electrodes comprise first bipolar RF electrodes, and wherein the second electrodes comprise second bipolar RF electrodes.

### Claim 33 (depends on 21)

The method of claim 21 wherein the first electrodes and second electrodes comprise monopolar electrodes, and wherein
thermally inhibiting neural communication via thermal RF energy from the first electrodes comprises delivering RF energy in a monopolar fashion between the first electrodes and a ground electrode such that the resulting energy field attenuates neural communication along the neural fibers innervating the first kidney; and
thermally inhibiting neural communication via thermal RF energy from the second electrodes comprises delivering RF energy in a monopolar fashion between the second electrodes and the ground electrode such that the resulting energy field attenuates neural communication along the neural fibers innervating the second kidney.

### Claim 34

A method for catheter-based renal denervation, the method comprising:
intravascularly positioning a first catheter having an expandable distal first balloon within a first renal artery of a human patient, wherein the first balloon is sized and shaped for the first renal artery;
at least partially ablating nerves along the first renal artery via electric energy from first bipolar RF electrodes arranged about a surface of the first balloon;
removing the first catheter from the patient;
intravascularly positioning a second catheter having an expandable distal second balloon within a second renal artery of the patient, wherein the second balloon is sized and shaped for the second renal artery and comprises a different size and/or shape than the first balloon; and
at least partially ablating nerves along the second renal artery via electric energy from second bipolar RF electrodes arranged about a surface of the second balloon.

### Claim 35 (depends on 34)

The method of claim 34 wherein the individual first bipolar RF electrodes comprise at least one pair of first bipolar contacts, and wherein the individual second bipolar RF electrodes comprise at least one pair of second bipolar contacts.

### Claim 36 (depends on 34)

The method of claim 34 wherein at least partially ablating the nerves along the first renal artery and the nerves along the second renal artery results in a therapeutically beneficial reduction in blood pressure in the patient.

### Claim 37 (depends on 34)

The method of claim 34 wherein at least partially ablating the nerves along the first renal artery and the nerves along the second renal artery results in a therapeutically beneficial reduction in central sympathetic overactivity of the patient.

### Claim 38 (depends on 34)

The method of claim 34, further comprising:
monitoring contact between the first bipolar RF electrodes and a wall of the first renal artery; and
monitoring contact between the second bipolar RF electrodes and a wall of the second renal artery.

### Claim 39 (depends on 38)

The method of claim 38 wherein monitoring contact between the first and second bipolar RF electrodes and the walls of the first and second renal arteries, respectively, comprises monitoring impedance and/or temperature.

### Claim 40 (depends on 38)

The method of claim 38, further comprising adjusting a treatment parameter in response to the monitoring.
